Study Evaluating Venlafaxine ER in Children and Adolescents With Social Anxiety Disorder

A Double-Blind, Placebo-Controlled, Parallel-Group, Flexible-Dose Study of Venlafaxine ER In Children and Adolescent Outpatients With Social Anxiety Disorder

To determine the anxiolytic efficacy, safety, and tolerability of a flexible-dose of venlafaxine extended release (ER) administered for 16 weeks in the treatment of children and adolescent outpatients with social anxiety disorder (generalized) in a placebo-controlled study.

Inclusion Criteria:

• Male or female outpatient
• 8-17 year old
• diagnosis of Social Anxiety Disorder

Exclusion Criteria:

• concomitant psychiatric or medical disorders which interfere with safety or assessment